The Digital DNA series explores the role of large-scale genetic testing in science, industry and society. We aim to understand both the benefits and risks of this emerging technology and see what the future may hold. When Ralph Taylor registered his new business, he attempted to declare it as a disadvantaged business enterprise. Businesses headed […]
Data is at the heart of applicable genomics. As the volume and depth of genomic data grows, bioinformaticians are translating the data into interpretable patterns leading to new biological insight.
The Digital DNA series will explore the role of large-scale genetic testing in science, industry and society. We aim to understand both the benefits and risks of this emerging technology and see what the future may hold. In the first of our Digital DNA series, we talked to Dr. Peter Ney, a researcher in the […]
Biobank 2019 – An Interview with Anthony Whetton, Professor of Cancer Cell Biology, University of Manchester
The UK Biobank’s 2019 scientific conference concluded this month. We talked to speaker Anthony Whetton, Professor of Cancer Cell Biology at the University of Manchester and Director of the Stoller Biomarker Discovery Centre, about large-scale multi-omic data within UK Biobank.
From 1 July, international scientists looking to use Chinese genetic material and data must have at least on Chinese collaborator working with them, according to new regulations. This follows a trend as individuals and organisations realise the value of their genetic data.
As part of the Next Generation Children project at Addenbrooke’s Hospital and Cambridge University, all seriously ill children in England with unexplained disorders will be able to have their genomes analysed from 2020. The project should mean quicker diagnoses for families in the future.
The FDA has cleared the most expensive drug yet, Novartis’ gene therapy drug Zolgensma, for introduction to the market. Zolgensma, created to combat spinal muscular atrophy, has been priced at $2.125 million, or $425,000 annually over five years.
It has now been 16 years since the Human Genome Project sequenced the first ever human genome: in that time, as has been mentioned in previous editions of this report, more than 500,000 genomes have been sequenced, generating enough data to drastically raise computational resource usage and create a need for rapid innovation to offset […]
GEDMatch, the DNA database which made news recently for its instrumental role in solving cold criminal cases in the US, has blocked law enforcement from accessing information for the millions of people on its system.
UK Biobank has released a vast tranche of genetic data to health researchers around the world, offering an unprecedented resource to enhance understanding of human biology and aid in therapeutic discovery. This follows a brief exclusive research period for Regeneron and GSK. Additional tranches of data will be released over the next two years.
Two molecules which switch off CRISPR could be used to make gene editing therapies safer in the future. Harvard University’s Amit Choudhary and his colleagues said the molecules could stop CRISPR making unintended changes to DNA, potentially harming the individual.
Genetic research is a big data problem without researchers generally having access to this “big” genomic and medical data. Not only has it been nearly impossible to access enough relevant data to support research, but analysing the data has been slow and challenging due to its sheer volume. To counter this, in recent years a number of pharmaceutical companies have announced large-scale collaborations around genomic data to uncover novel drug targets, validate existing drug pipelines, predict response, and expand therapeutics use. We discuss some of the biggest and most recent.
Front Line Genomics’ “Biodata Analysis and Management – Genome Analytics, Interoperability, and Data Life Cycle” report isn’t just an update of our old Genomic Data 101 guides: packed with new information on AI and machine learning,. data discoverability and data interoperability, it is much much more.
Genomic compression expert PetaGene has become a NetApp Alliance Partner, the company announced recently, a move set to improve performance and reduce costs for researchers using large datasets within the genomics field.
Cambridge and London researchers have created a database of DNA mutation “fingerprints” which can be used to determine the environmental factors contributing to a patient’s tumour. The study, published in Cell journal, can determine 41 different environmental agents linked to cancer, including the traces left in lung tumours by chemicals linked particularly to tobacco smoke.
Compression software company Petagene has announced the addition of “Petagene Protect” to its suite of genomic data projects, giving users the ability to encrypt and manage access to genomic data, as well as ensuring compliance with all relevant regulations.